Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Respiratory Medicine

Journal Scan / Research · August 29, 2024

Safety and Tolerability of Bexotegrast in the Treatment of Patients With IPF

American Journal of Respiratory and Critical Care Medicine

 

Additional Info

American Journal of Respiratory and Critical Care Medicine
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Am J Respir Crit Care Med 2024 Aug 15;210(4)424-434, L Lancaster, V Cottin, M Ramaswamy, WA Wuyts, RG Jenkins, MB Scholand, M Kreuter, C Valenzuela, CJ Ryerson, J Goldin, GHJ Kim, M Jurek, M Decaris, A Clark, S Turner, CN Barnes, HE Achneck, GP Cosgrove, ÉA Lefebvre, KR Flaherty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading